由于交易量低，Poolbeg Pharma 自愿将普通股从 OTCQB 退市。 Poolbeg Pharma voluntarily delists ordinary shares from OTCQB due to low trading volume.

英国生物制药公司 Poolbeg Pharma PLC 因交易量低而自愿将普通股从 OTCQB 退市，但仍在伦敦证券交易所 AIM 市场上市，股票代码为“POLB”。 Poolbeg Pharma PLC, a UK biopharmaceutical firm, voluntarily delists ordinary shares from OTCQB due to low trading volume, retaining listing on London Stock Exchange's AIM Market with ticker "POLB." 该公司继续专注于针对罕见病和孤儿病等尚未满足的医疗需求的创新药物。 The company continues its focus on innovative medicines for high unmet medical needs, including rare and orphan diseases. Poolbeg 的目标是在适当的时候在纳斯达克等美国国家证券交易所上市。 Poolbeg aims to list on a U.S. national securities exchange like Nasdaq when appropriate.